Daiichi Sankyo Company, , an innovative global healthcare company, has appointed Hiroyuki Okuzawa, 62, to succeed Sunao Manabe, DVM, Ph.D. as chief executive officer (CEO), effective April 1, 2025. Dr ...
Daiichi Sankyo’s Q3 FY2024 results reflect strong performance in oncology, driven by ENHERTU’s market leadership and robust sales growth across regions. Despite regulatory delays for Datroway ...
Japanese drugmaker Daiichi Sankyo (TYO: 4568) has appointed Hiroyuki Okuzawa to succeed Sunao Manabe, as chief executive (CEO), effective April 1, 2025. Dr Manabe will transition from his current role ...
Daiichi Sankyo promoted Hiroyuki Okuzawa to CEO, and he will take over from Sunao Manabe on April 1.
“Speech is how we naturally communicate. This funding moves us closer to a world where digital interactions happen by voice—fluid, natural and as effortless as a conversation,” said ...
That nod, which covers a restricted population of only patients who have one or no copies of the ApoE4 ... AstraZeneca and Daiichii Sankyo’s antibody-drug conjugate (ADC) Datroway was ...
(RTTNews) - Japanese healthcare firm Daiichi Sankyo Co., Ltd (DSKYF.PK) announced Friday the appointment of Hiroyuki Okuzawa as Chief Executive Officer, succeeding Sunao Manabe, with effect from ...
TOKYO, January 31, 2025--(BUSINESS WIRE)--Daiichi Sankyo Company, Ltd (TSE: 4568) has appointed Hiroyuki Okuzawa, 62, to succeed Sunao Manabe, DVM, Ph.D. as Chief Executive Officer (CEO ...
eight important key data readouts just in a period of one year and so there'll be a very exciting time for data for Daiichi Sankyo in fiscal year 2025. Okay, that's it for my side and let me turn ...
Daiichi Sankyo Company, Ltd (TSE: 4568) has appointed Hiroyuki Okuzawa, 62, to succeed Sunao Manabe, DVM, Ph.D. as Chief Executive Officer (CEO), effective April 1, 2025. Dr. Manabe will ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback